Systematic Ambulatory ECG Monitoring for Preventing Life-Threatening Cardiovascular Events Following TAVR.
Quentin, F., Isabelle, N., Pedro, C.G., Marisa, A., Carla, B.G., Emilie, P.B., François, P., & Josep, R.C. (2026). Systematic Ambulatory ECG Monitoring for Preventing Life-Threatening Cardiovascular Events Following TAVR.. Circ Cardiovasc Interv. https://doi.org/10.1161/CIRCINTERVENTIONS.125.016288
Quentin F, Isabelle N, Pedro CG, Marisa A, Carla BG, Emilie PB, et al. Systematic Ambulatory ECG Monitoring for Preventing Life-Threatening Cardiovascular Events Following TAVR.. Circ Cardiovasc Interv. 2026; doi: 10.1161/CIRCINTERVENTIONS.125.016288
Quentin F, Isabelle N, Pedro CG, et al. Systematic Ambulatory ECG Monitoring for Preventing Life-Threatening Cardiovascular Events Following TAVR.[J]. Circ Cardiovasc Interv. 2026. DOI: 10.1161/CIRCINTERVENTIONS.125.016288.
@article{quentin2026,
author = {Fischer Quentin and Nault Isabelle and Cepas-Guillén Pedro and Avvedimento Marisa and Benavent-Garcia Carla and Pelletier-Beaumont Emilie and Philippon François and Rodés-Cabau Josep},
title = {Systematic Ambulatory ECG Monitoring for Preventing Life-Threatening Cardiovascular Events Following TAVR.},
journal = {Circ Cardiovasc Interv},
year = {2026},
doi = {10.1161/CIRCINTERVENTIONS.125.016288},
note = {PMID: 42059075},
}
TY - JOUR AU - Fischer Quentin AU - Nault Isabelle AU - Cepas-Guillén Pedro AU - Avvedimento Marisa AU - Benavent-Garcia Carla AU - Pelletier-Beaumont Emilie AU - Philippon François AU - Rodés-Cabau Josep TI - Systematic Ambulatory ECG Monitoring for Preventing Life-Threatening Cardiovascular Events Following TAVR. T2 - Circ Cardiovasc Interv PY - 2026 DO - 10.1161/CIRCINTERVENTIONS.125.016288 AN - PMID:42059075 ER -
Although ambulatory ECG (AECG) monitoring has been assessed after transcatheter aortic valve replacement (TAVR), its impact on life-threatening cardiovascular events remains unclear. This study aimed to evaluate whether systematic AECG monitoring after TAVR reduces life-threatening cardiovascular events during the first year of follow-up. The study included 1217 consecutive patients who underwent TAVR and were discharged without a permanent pacemaker. Of these, 211 consecutive patients received systematic 14-day AECG monitoring at discharge as part of the RECORD registry. The remaining 1006 patients who underwent TAVR within the 3 years before and after the registry period without systematic AECG monitoring constituted the control group. The primary end point was a composite of sudden cardiac death, syncope/presyncope due to symptomatic arrhythmias, or stroke at 1-year. Baseline and procedural characteristics were similar between groups, except for a higher use of self-expandable valves in the control group (P=0.005). Systematic AECG monitoring was associated with a lower incidence of the primary end point (1.9% versus 6.6%; adjusted hazard ratio, 0.27 [0.10-0.74]; P=0.011), mainly driven by a lower rate of sudden death or arrhythmic syncope/presyncope (0.9% versus 4.0%; adjusted hazard ratio, 0.22 [0.05-0.89]; P=0.034). All sudden death cases occurred in the control group, at a median of 96 (33-235) days after TAVR. New-onset atrial fibrillation was diagnosed in 8.9% of the systematic AECG patients (versus 1.8% in the control group; adjusted hazard ratio, 5.31 [2.47-11.38]; P<0.001), leading to new oral anticoagulation in 71.4% of cases. Stroke and permanent pacemaker implantation rates at 1 year were similar between groups, although permanent pacemaker implantation occurred earlier in the AECG group (25 versus 104 days; P<0.001). Systematic AECG monitoring after TAVR enables earlier detection of severe arrhythmias and is associated with fewer life-threatening cardiovascular events within 1 year. These findings support the need for a randomized trial. URL: https://www.clinicaltrials.gov; Unique identifier: NCT04298593.